Global Oncology | Specialty

The OncLive® Global Oncology condition center page is a comprehensive resource for clinical news and international expert insights on treatment of patients with cancer. This page features articles focused on ex-US regulatory news, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing global research in oncology care.

Atezolizumab/Bevacizumab Approved in Europe for Advanced or Unresectable HCC

November 2nd 2020

The European Commission has approved the combination of atezolizumab plus bevacizumab for use in adult patients with advanced or unresectable hepatocellular carcinoma who have not been given previous systemic therapy.

Atezolizumab Plus Bevacizumab Approved in China for Hepatocellular Carcinoma

October 30th 2020

The China National Medical Products Administration has approved the combination of atezolizumab plus bevacizumab for use in patients with unresectable hepatocellular carcinoma who have not received previous systemic therapy.

Niraparib Approved in Europe for Frontline Maintenance in Advanced Ovarian Cancer

October 29th 2020

The European Commission has approved niraparib for use as a frontline monotherapy maintenance option in adult patients with advanced epithelial, high-grade ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response after platinum-based chemotherapy.

Approval Sought for Cabozantinib/Nivolumab for Unresectable, Advanced, or Metastatic RCC in Japan

October 27th 2020

A supplemental application was submitted to the Japanese Ministry of Health, Labour, and Welfare for Manufacturing and Marketing approval of the combination of cabozantinib plus nivolumab for the treatment of patients with unresectable, advanced, or metastatic renal cell carcinoma.

Dr. Gronchi on the Results of the TRASTS Trial in Soft Tissue Sarcoma

October 23rd 2020

Alessandro Gronchi, MD, discusses ​the results of the ​phase 2 TRASTS trial in soft tissue sarcoma.

Dr. Azad on the Significance of the PROfound Trial in mCRPC

October 23rd 2020

Arun Azad, PhD, discusses the significance of the PROfound trial in metastatic castration-resistant prostate cancer.

Dr. McDermott on Preventing Recurrence of High-Risk Prostate Cancer

October 21st 2020

Ray McDermott, discusses preventing recurrence in patients with very high-risk prostate cancer.

Dr. Lwin on the Design of the LEAP-005 Trial in Pretreated Advanced Solid Tumors

October 20th 2020

Zarnie Lwin, MBBS, FRACP, discusses the design of the phase 2 LEAP-005 trial in previously treated patients with advanced solid tumors.

Dr. Pautier on Results of the LMS-02 Trial in Uterine and Soft Tissue Sarcomas

October 16th 2020

Patricia Pautier, MD, discusses the results of the phase 2 LMS-02 trial with doxorubicin and trabectedin in ​uterine and soft tissue leiomyosarcoma.

First-in-Human T-Cell Therapy Warrants Further Investigation in HCC

October 9th 2020

New data showing efficacy and tolerability with ADP-A2AFP, alpha-fetoprotein–directed specific peptide enhanced affinity receptor T-cells, suggest that further research evaluating the 5 billion or more cell dosing regimen is warranted in hepatocellular carcinoma.

Dr. Concin on the Rationale for the LIO-1 Trial in Advanced Gynecologic Malignancies

October 7th 2020

Nicole Concin, MD, discusses the rationale for the ​phase 1/2 LIO-1 trial in advanced gynecologic malignancies.

Dr. Pautier on Challenges With Drug Development in Leiomyosarcoma

October 6th 2020

Patricia Pautier, MD, discusses limitations in leiomyosarcoma.

Bavituximab/Pembrolizumab Combo Is Active in Advanced Gastric/GEJ Cancer

October 6th 2020

The combination of bavituximab and pembrolizumab demonstrated synergistic antitumor activity and was well tolerated in patients with pretreated advanced gastric or gastroesophageal junction cancer.

Dr. Kristeleit on QoL With Dostarlimab in dMMR/MSI-H Endometrial Cancer

September 30th 2020

Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, discusses the importance of patient-reported outcomes in the phase 1 GARNET trial in advanced or recurrent mismatch repair deficient/microsatelite instability-high endometrial cancer.

Dr. McDermott on Rationale for Darolutamide Plus ADT/Radiation in High-Risk Prostate Cancer

September 30th 2020

Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, discusses the rationale for the addition of darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk prostate cancer.

Dr. Eggermont on the Rationale for Evaluating Adjuvant Pembrolizumab in Advanced Melanoma

September 30th 2020

Alexander M. M. Eggermont, MD, PhD, discusses the rationale for the phase 3 EORTC 1325/KEYNOTE-054 trial, ​evaluating adjuvant pembrolizumab versus placebo, in advanced melanoma.

Dr. Welslau on the Rationale for the REFLECT Trial With Rituximab Biosimilar

September 22nd 2020

Manfred Welslau, MD, discusses the rationale of the prospective REFLECT trial with the rituximab biosimilar SDZ-RTX in patients with diffuse large B-cell lymphoma.

Dr. Stratigos the Rationale to Evaluate Cemiplimab in Locally Advanced BCC

September 18th 2020

Alexander J. Stratigos, MD, discusses the rationale to evaluate cemiplimab-rwlc in locally advanced basal cell carcinoma.

Dr. Crown on the Role of Eribulin Mesylate in TNBC

September 17th 2020

John Crown, BCh, BAO, BSc, MD, MBA, discusses the role of eribulin mesylate in triple-negative breast cancer.

PREVIOUS PAGE